Royalty Pharma

Royalty Pharma is a Nasdaq-listed company that acquires royalties on biopharmaceutical products and funds work in the life sciences. It deals directly with research institutions, inventors and biopharma companies.

Its business sits between science, medicine and investing. Instead of buying whole companies, it takes the passive royalty streams attached to medicines.

Products and services

• Royalties on approved products: purchase of existing royalties on marketed biopharmaceutical products.
• Synthetic royalties: new royalty arrangements agreed directly with an innovator.
• Royalty monetisation: cash to innovators in return for an existing royalty.
• Development co-funding: capital toward clinical development of a product candidate, repaid through a royalty.
• Late-stage candidates: royalties on products in the later phases of clinical development.

Customers and markets

Research institutions, inventors and biopharma companies. It can also work with strategic acquirers that buy firms owning both operating assets and passive royalties.

Key facts

• Listing: Nasdaq (RPRX)
• Sector: biopharmaceutical royalties and life sciences funding